United States · Series C startup

Who invested in Regenesis Biomedical

One round we have observed, with the 3 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Medical Devices

Funding summaryUpdated 26 Oct 2026

$5.3Mraised across 1 round since 2011, from 1 source

Latest round
Series C, $5.3MJun 2011
Investors
3
See who backed them

The rounds

  1. Jun 2011
    Series C$5.3M

    Reported by finsmes.comSEC filing: $5.2M sold, first sale Jun 2011

Founders and team

From the SEC filings it signed: 2 on the team.

  • Dennis GengeExecutive Officeri
  • Virginia RybskiExecutive Officer, Directori

On the board, as filediChuck LundenHenry NewmanJack AhrensJohn VorisPeter SheehanTom Greer

Everyone who backed them

Sol Cap IncGrowth equity1round
TGap VenturesGrowth equity1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Regenesis Biomedical

Who invested in Regenesis Biomedical?

Regenesis Biomedical's investors include Fulcrum Equity Partners, Sol Cap Inc and TGap Ventures.

How much has Regenesis Biomedical raised?

Regenesis Biomedical has raised $5.3M across 1 round since 2011.

When did Regenesis Biomedical last raise?

Regenesis Biomedical's most recent round was a Series C of $5.3M in Jun 2011.

What was Regenesis Biomedical's biggest round?

Its most recent round, $5.3M in Jun 2011, is also its largest on record.

Who backed Regenesis Biomedical first?

Regenesis Biomedical's first round on record, in Jun 2011, was backed by Fulcrum Equity Partners, Sol Cap Inc and TGap Ventures.

What stage is Regenesis Biomedical at?

Regenesis Biomedical's latest named round is a Series C, in Jun 2011.

Where is Regenesis Biomedical based?

Regenesis Biomedical is based in the United States.

Companies like Regenesis Biomedical

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.